Connection

Antonio Giordano to Female

Back to Details
This is a "connection" page, showing publications Antonio Giordano has written about Female.
Antonio Giordano
Connection Strength
0.315
Female
  1. Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS One. 2019; 14(11):e0224420.
    View in: PubMed
    Score: 0.037
  2. Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol. 2018 08; 41:59-65.
    View in: PubMed
    Score: 0.033
  3. Clinical Features and Outcomes of Pasteurella multocida Infection. Medicine (Baltimore). 2015 Sep; 94(36):e1285.
    View in: PubMed
    Score: 0.028
  4. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res. 2013 Mar 15; 19(6):1596-602.
    View in: PubMed
    Score: 0.023
  5. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012 Nov; 11(11):2526-34.
    View in: PubMed
    Score: 0.023
  6. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Res Treat. 2011 Sep; 129(2):451-8.
    View in: PubMed
    Score: 0.021
  7. Critical Illness Polyneuropathy and Functional Outcome in Subjects with Covid-19: Report on Four Patients and a Scoping Review of the Literature. J Rehabil Med. 2022 Apr 07; 54:jrm00257.
    View in: PubMed
    Score: 0.011
  8. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. Int J Med Sci. 2021; 18(10):2245-2250.
    View in: PubMed
    Score: 0.010
  9. An observational study and randomized trial of stress reactivity in cancer disparities. Health Psychol. 2020 Sep; 39(9):745-757.
    View in: PubMed
    Score: 0.010
  10. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019 10; 20(10):1360-1369.
    View in: PubMed
    Score: 0.009
  11. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. J Cell Physiol. 2019 06; 234(6):7708-7717.
    View in: PubMed
    Score: 0.009
  12. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. J Cell Physiol. 2018 Mar; 233(3):2313-2323.
    View in: PubMed
    Score: 0.008
  13. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 2017 May 30; 8(22):35656-35668.
    View in: PubMed
    Score: 0.008
  14. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation. Oncotarget. 2017 Apr 25; 8(17):28939-28958.
    View in: PubMed
    Score: 0.008
  15. Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model. Oncotarget. 2015 Dec 08; 6(39):42091-104.
    View in: PubMed
    Score: 0.007
  16. Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS One. 2015; 10(7):e0132710.
    View in: PubMed
    Score: 0.007
  17. Overexpression and Nucleolar Localization of ?-Tubulin Small Complex Proteins GCP2 and GCP3 in Glioblastoma. J Neuropathol Exp Neurol. 2015 Jul; 74(7):723-42.
    View in: PubMed
    Score: 0.007
  18. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res. 2015 Jan 09; 17:2.
    View in: PubMed
    Score: 0.007
  19. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost. 2015 Mar; 113(3):593-8.
    View in: PubMed
    Score: 0.007
  20. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 2014 Sep 16; 16(5):440.
    View in: PubMed
    Score: 0.007
  21. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One. 2014; 9(1):e83113.
    View in: PubMed
    Score: 0.006
  22. The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor a in breast cancer. PLoS One. 2013; 8(2):e55355.
    View in: PubMed
    Score: 0.006
  23. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012 Aug; 12(4):264-9.
    View in: PubMed
    Score: 0.006
  24. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67.
    View in: PubMed
    Score: 0.005
  25. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer. 2012 Feb 15; 130(4):808-16.
    View in: PubMed
    Score: 0.005
  26. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44?CD24lo cancer stem cell phenotype. Eur J Cancer. 2011 Jul; 47(10):1527-36.
    View in: PubMed
    Score: 0.005
  27. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer. 2005 12; 12(4):721-47.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.